Drug
Rifaximin
Rifaximin: highest development phase Post-Market, developed by Bausch Health, Cipla. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bausch Health, Cipla
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rifaximin 200 mg Tablet NCT07285785 | Post-Market | Diarrhea |
| Rifaximin NCT01842581 | Post-Market | Hepatic Encephalopathy |
| Rifaximin NCT03818672 | Post-Market | Severe Hepatic Impairment |
| Rifaximin NCT01654939 | Post-Market | HIV |
| RIFAXIMIN | Approved | |
| Rifaximin NCT00686920 | Phase 3 | Hepatic Encephalopathy |
| Rifaximin NCT00259155 | Phase 2 | Irritable Bowel Syndrome |
Latest
No recent events.
Follow Rifaximin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.